Analyzing...
Loading company...
Alembic Pharmaceuticals Ltd. is a research and development pharmaceutical company, which engages in the research, development, manufacture, and market of generic and branded pharmaceutical products. The company is headquartered in Vadodara, Gujarat and currently employs 14,593 full-time employees. The company went IPO on 2011-09-17. The firm is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). The company delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. The company has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹7,345 Cr revenue.
COGS 27.0%, employees 23.6%.
“EBITDA margin, I think, the only guidance I've given in the past, and I continue to stay by it, is that if you see fundamentally what will happen over the next couple of years, we ”
“I expect The US to go between 10% to 12%, for the full on a full year basis.”
“revenue grew at 12% year on year to”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 11.9%▲ | 10.3% |
| ROCE | 12.8%▼ | 13.7% |
| Net Margin | 9.1%▲ | 7.6% |
| EBITDA Margin | 14.9%▼ | 15.4% |
| Debt To Equity | 0.24x▲ | 0.15x |
| Rev Growth 3yr | 9.4%▼ | 10.0% |
| EPS Growth 3yr | 25.4%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7,345 Cr +10.1% | ₹6,672 Cr +7.1% | ₹6,229 Cr +10.2% | ₹5,653 Cr +6.5% | ₹5,306 Cr -1.6% | ₹5,393 Cr +17.1% | ₹4,606 Cr +17.1% | ₹3,935 Cr |
| Other Income | ₹54 Cr +27.9% | ₹43 Cr +50.3% | ₹28 Cr +931.6% | ₹3 Cr -94.6% | ₹50 Cr +403.8% | ₹10 Cr +102.7% | ₹5 Cr -47.3% | ₹9 Cr |
| Total Income | ₹7,399 Cr +10.2% | ₹6,715 Cr +7.3% | ₹6,257 Cr +10.6% | ₹5,655 Cr +5.6% | ₹5,356 Cr -0.9% | ₹5,403 Cr +17.2% | ₹4,611 Cr +16.9% | ₹3,944 Cr |
| COGS | ₹1,984 Cr +10.7% | ₹1,793 Cr +4.6% | ₹1,715 Cr +0.4% | ₹1,709 Cr +18.1% | ₹1,446 Cr +15.0% | ₹1,257 Cr +21.0% | ₹1,039 Cr +4.7% | ₹993 Cr |
| ₹6,639 Cr +10.3% | ₹6,021 Cr +7.1% | ₹5,624 Cr +6.7% | ₹5,270 Cr +11.3% | ₹4,736 Cr +17.4% | ₹4,035 Cr +13.1% | ₹3,567 Cr +11.7% | ₹3,195 Cr | |
| Profit Before Tax | ₹694 Cr -1.8% | ₹706 Cr +11.6% | ₹633 Cr +64.1% | ₹386 Cr -37.8% | ₹620 Cr -54.7% | ₹1,368 Cr +36.8% | ₹1000 Cr +33.4% | ₹749 Cr |
| Exceptional Items | (₹67 Cr) ↓ Decline | ₹13 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹44 Cr) | ₹0.00 Cr |
| ₹23 Cr -81.5% | ₹125 Cr +682.0% | ₹16 Cr +27.0% | ₹13 Cr -87.9% | ₹104 Cr -58.8% | ₹253 Cr +27.2% | ₹199 Cr +27.1% | ₹157 Cr | |
| Net Profit | ₹1,140 Cr +95.9% | ₹582 Cr -5.5% | ₹616 Cr +80.1% | ₹342 Cr -34.4% | ₹521 Cr -54.6% | ₹1,147 Cr +43.2% | ₹801 Cr +37.3% | ₹583 Cr |
| Profit (Owners) | ₹1,147 Cr +96.6% | ₹583 Cr -5.3% | ₹616 Cr +80.1% | ₹342 Cr -37.3% | ₹546 Cr -53.7% | ₹1,178 Cr +42.1% | ₹829 Cr ↑ Recovery | (₹1 Cr) |
| Minority Interest | (₹7 Cr) -376.1% | (₹1 Cr) | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹25 Cr) +21.7% | (₹32 Cr) -12.4% | (₹28 Cr) ↓ Decline | ₹584 Cr |
| Other Comprehensive Income | ₹25 Cr +349.4% | ₹6 Cr ↑ Recovery | (₹11 Cr) ↓ Decline | ₹13 Cr +854.0% | ₹1 Cr ↑ Recovery | (₹4 Cr) -102.8% | (₹2 Cr) ↓ Decline | ₹6 Cr |
| EPS | ₹58.34 | ₹29.68 | ₹31.33 | ₹17.40 | ₹27.76 | ₹59.94 | ₹43.97 | (₹0.06) |
| Diluted Shares | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹19 Cr | ₹19 Cr |
| Profit Or Loss Of Associates | ₹0.23 Cr -73.6% | ₹0.87 Cr ↑ Recovery | (₹0.98 Cr) +96.8% | (₹31 Cr) ↓ Decline | ₹5 Cr -83.3% | ₹32 Cr | ₹0.05 Cr ↑ Recovery | (₹9 Cr) |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 28, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Prucalopride Tablets,...
Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of Post Results Conference Call on Tuesday, 4th August, 2026
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 18, 2026, titled "Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative...
Alembic Pharmaceuticals Limited has informed the Exchange about General Updates Disclsoure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Alembic Pharmaceuticals Limited has informed the Exchange regarding 'Specimen Copy Of The Letter Sent To The Shareholders Under Regulation 36(1)(b) Of SEBI LODR'.
Alembic Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 29-Jul-2026.
Alembic Pharmaceuticals Limited has informed the Exchange regarding Notice of 16th Annual General Meeting to be held on August 05, 2026 at 4:00 p.m. IST.
Alembic Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 19, 2026, titled "Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Table...
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 12, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Tretinoin Cream USP, 0...
Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 11, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Larotrectinib Caps...